Follow the entities shaping the evidence.

…ized mouse model through interaction with human APC, suggesting NY-ESO specific CD4+ T cells could target MHC II negative tumors.Abstr…

…tibody pembrolizumab (vibo/pembro) with or without docetaxel in mNSCLC previously treated with anti-PD-(L)1 therapy and platinum chemo…

…confined to the abdominopelvic cavity, adequate organ function, ECOG performance status ≤1, and suitable for peritoneal catheter insertion. Patients un…

…Ref Funder ID: 10.13039/100004755), which provides avelumab and tuvusertib.Trial Registration NCT05947500References Vendetti FP, Karukonda…

…e, 33.7 months by RECIST 1.1) in patients with anti-PD-1-failed melanoma, with mainly grade 1/2 constitutional-type side effects. The tr…

…ved). The best overall response was SD (RECIST 1.1).Conclusions VAX014 monotherapy is well tolerated with evidence of activity in both…

…hbehani GK, Riddell S, Cripe T, Cairo MS. Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vit…

…ing tumor acidity and reshaping the metabolic microenvironment, pramlintide may enhance immune cell trafficking and function, supporting it…

…mbrolizumab (n = 5). Tyrosine kinase inhibitors (TKIs) included lenvatinib (n = 16) and sorafenib (n = 13).Results With a median follow-up…

…ti-PD-1 or anti-PD-L1 antibodies) plus concurrent chemotherapy (cisplatin or carboplatin) is now part of the standard of care for non-sma…

…activity compared to vehicle, WTX-124 alone or a single dose of WTX-330. Multiplex immunofluorescence analysis of tumors revealed that …

…–56.Ethics Approval All animal experiments were approved by the Massachusetts Institute of Technology institutional animal care and use committee and conducted in co…